디지털 바이오마커 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Digital Biomarkers Market reached USD 3.8 billion in 2024 and is expected to expand significantly at a CAGR of 28.8% between 2025 and 2034. Digital biomarkers are objective, measurable data that reflect an individual's physiological, behavioral, or environmental condition. They are collected through advanced digital tools such as wearables, mobile applications, and sensors, offering crucial insights into a person's health status, disease progression, and treatment responses in real-world settings. As healthcare becomes increasingly data-driven, digital biomarkers are transforming how conditions are monitored, detected, and managed. These technologies not only provide real-time data that can detect subtle changes in health but also pave the way for proactive healthcare strategies, offering the potential to revolutionize preventative care. By enabling continuous monitoring of health indicators, digital biomarkers are changing the landscape of disease management and helping clinicians make more informed decisions.

The market is segmented into wearables, mobile applications, sensors, and other digital tools. The wearable segment currently dominates the market, holding a 42.5% share in 2024. Wearables are particularly powerful as they allow for continuous, real-time tracking of key physiological and behavioral indicators, such as heart rate, sleep patterns, physical activity, and glucose levels. Unlike traditional clinical assessments, wearables offer the ability to track these indicators around the clock, providing more detailed insights and the ability to detect even minor changes in health that could signal the onset of disease. This continuous monitoring not only enhances early detection but also enables timely medical intervention, ultimately improving patient outcomes.

When considering clinical practices, digital biomarkers are classified into diagnostic, monitoring, predictive, and prognostic categories. The monitoring biomarkers segment led the market with a 45.8% share in 2024 and is poised for substantial growth, expected to reach USD 21.4 billion by 2034. Monitoring biomarkers are crucial for detecting early signs of diseases, especially chronic conditions like diabetes and Alzheimer's disease. They can detect subtle changes in an individual's health, enabling more effective and timely interventions. As the demand for proactive health management increases, the role of digital biomarkers in monitoring conditions will continue to grow, enhancing the overall effectiveness of healthcare.

The U.S. digital biomarkers market is set to reach USD 16.5 billion by 2034, driven by the country's robust technological infrastructure and a strong innovation ecosystem. The presence of major tech companies in artificial intelligence, machine learning, and cloud computing has accelerated the development of advanced digital biomarkers. In addition, the widespread adoption of wearable devices, such as fitness trackers and continuous glucose monitors, has played a significant role in the growing popularity of digital biomarkers. Consumer demand for these technologies continues to drive market expansion, further fueling advancements in this transformative healthcare sector.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Advancements in AI and Machine learning
    • 3.2.1.3 Adoption of wearable devices
    • 3.2.1.4 Growing focus on remote monitoring
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs of advanced devices
    • 3.2.2.2 Lack of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Wearable
• 5.3 Mobile based applications
• 5.4 Sensors
• 5.5 Others types

Chapter 6 Market Estimates and Forecast, By Clinical Practice, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diagnostic digital biomarkers
• 6.3 Monitoring digital biomarkers
• 6.4 Predictive and prognostic digital biomarkers
• 6.5 Other clinical practices

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Cardiovascular and metabolic disorders (CVMD)
• 7.3 Diabetes
• 7.4 Respiratory disorders
• 7.5 Psychiatric disorders
• 7.6 Sleep and movement diseases
• 7.7 Neurological disorders
• 7.8 Musculoskeletal disorders
• 7.9 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Healthcare providers
• 8.3 Payers
• 8.4 Pharmaceutical and biotechnology companies
• 8.5 Academic and research institutions

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 ActiGraph
• 10.2 AliveCor
• 10.3 Altoida
• 10.4 Amgen Inc.
• 10.5 Adherium Limited
• 10.6 Aural Analytic
• 10.7 Brainomix
• 10.8 Biogen
• 10.9 Clario
• 10.10 Empatica Inc.
• 10.11 Evidation Health Inc.
• 10.12 IXICO plc
• 10.13 Koneksa
• 10.14 Sonde Health, Inc.
• 10.15 Vivo Sense